Tags

Type your tag names separated by a space and hit enter

Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.

Abstract

OBJECTIVE

To determine whether long-term transfusion improves growth in children with sickle cell anemia.

STUDY DESIGN

In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC). Transfusions were administered every 3 to 5 weeks, and hemoglobin S levels were maintained at 30% pretransfusion for an average of 2 years. Serial height and weight measurements (obtained every 3 months), body mass index (BMI) values, and growth z-scores were analyzed.

RESULTS

Children in the CTX (n=53) and STC (n=41) groups were similar at baseline. After 24 months, the z-scores for height, weight, and BMI of those receiving CTX had improved significantly, whereas no changes occurred in the STC group. Patients in the CTX group approached normal height-for-age and weight-for-age z-scores. Patients from a large historical control group had significantly lower weight and height growth velocities than patients in the CTX group.

CONCLUSIONS

Patients in the Stroke Prevention Trial for Sickle Cell Anemia Study who received CTX had improved height and weight and BMI over a 2-year period. Higher hemoglobin levels resulting from transfusion may improve growth by lowering energy expenditure. In addition to the prevention of vasoocclusive events, CTX results in significant improvement in the growth of children with sickle cell disease.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    St. Jude Children's Research Hospital, Memphis, Tenn 38105, USA. winfred.wang@stjude.org

    , , , , , ,

    Source

    The Journal of pediatrics 147:2 2005 Aug pg 244-7

    MeSH

    Adolescent
    Anemia, Sickle Cell
    Antisickling Agents
    Blood Transfusion
    Body Height
    Body Weight
    Child
    Child, Preschool
    Growth
    Humans
    Hydroxyurea
    Linear Models
    Stroke

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    16126058

    Citation

    Wang, Winfred C., et al. "Effect of Long-term Transfusion On Growth in Children With Sickle Cell Anemia: Results of the STOP Trial." The Journal of Pediatrics, vol. 147, no. 2, 2005, pp. 244-7.
    Wang WC, Morales KH, Scher CD, et al. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. J Pediatr. 2005;147(2):244-7.
    Wang, W. C., Morales, K. H., Scher, C. D., Styles, L., Olivieri, N., Adams, R., & Brambilla, D. (2005). Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. The Journal of Pediatrics, 147(2), pp. 244-7.
    Wang WC, et al. Effect of Long-term Transfusion On Growth in Children With Sickle Cell Anemia: Results of the STOP Trial. J Pediatr. 2005;147(2):244-7. PubMed PMID: 16126058.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial. AU - Wang,Winfred C, AU - Morales,Knashawn H, AU - Scher,Charles D, AU - Styles,Lori, AU - Olivieri,Nancy, AU - Adams,Robert, AU - Brambilla,Don, AU - ,, PY - 2004/09/17/received PY - 2005/01/04/revised PY - 2005/02/23/accepted PY - 2005/8/30/pubmed PY - 2005/9/28/medline PY - 2005/8/30/entrez SP - 244 EP - 7 JF - The Journal of pediatrics JO - J. Pediatr. VL - 147 IS - 2 N2 - OBJECTIVE: To determine whether long-term transfusion improves growth in children with sickle cell anemia. STUDY DESIGN: In the Stroke Prevention Trial for Sickle Cell Anemia Study, patients were randomized to receive long-term transfusion (CTX) or standard care (STC). Transfusions were administered every 3 to 5 weeks, and hemoglobin S levels were maintained at 30% pretransfusion for an average of 2 years. Serial height and weight measurements (obtained every 3 months), body mass index (BMI) values, and growth z-scores were analyzed. RESULTS: Children in the CTX (n=53) and STC (n=41) groups were similar at baseline. After 24 months, the z-scores for height, weight, and BMI of those receiving CTX had improved significantly, whereas no changes occurred in the STC group. Patients in the CTX group approached normal height-for-age and weight-for-age z-scores. Patients from a large historical control group had significantly lower weight and height growth velocities than patients in the CTX group. CONCLUSIONS: Patients in the Stroke Prevention Trial for Sickle Cell Anemia Study who received CTX had improved height and weight and BMI over a 2-year period. Higher hemoglobin levels resulting from transfusion may improve growth by lowering energy expenditure. In addition to the prevention of vasoocclusive events, CTX results in significant improvement in the growth of children with sickle cell disease. SN - 0022-3476 UR - https://www.unboundmedicine.com/medline/citation/16126058/Effect_of_long_term_transfusion_on_growth_in_children_with_sickle_cell_anemia:_results_of_the_STOP_trial_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0022-3476(05)00317-3 DB - PRIME DP - Unbound Medicine ER -